Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report

Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation. Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fu...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 9; no. 3; pp. 1694 - 1698
Main Authors Percy, Catherine, Schubert, Thomas, Galant, Christine, Kirchgesner, Thomas, Mazzeo, Filomena
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.03.2021
John Wiley and Sons Inc
Wiley
Subjects
Amputation
Biopsy
Case Report
Case Reports
Chemotherapy
FDA approval
larotrectinib
neoadjuvant
NTRK gene fusions
Pathology
Patients
Pediatrics
Radiation therapy
Response rates
Sarcoma
soft tissue sarcoma
Surgery
Tendons
Tumors
Belgium
neoadjuvant
larotrectinib
soft tissue sarcoma
NTRK gene fusions
Online AccessGet full text

Cover

More Information
Summary:Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation. Patients with soft tissue sarcomas should be assessed for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions as neoadjuvant treatment with larotrectinib may prevent amputation.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.3878